Source comparison
MK-677 Contraindications Comparison: Absolute vs Relative Risk
The distinction between absolute and relative contraindications determines whether MK-677 is excluded entirely or requires enhanced monitoring. This table maps the specific conditions, the biological mechanism that creates risk, and the threshold separating ex
This comparison does not assign a generated winner or score.
- The distinction between absolute and relative contraindications determines whether MK-677 is excluded entirely or requires enhanced monitoring. This table maps the specific conditions, the biological mechanism that creates risk, and the threshold separating exclusion from conditional inclusion.
- Malignancy
- Active cancer of any stage or type
- History of cancer in remission >2 years (solid tumors) or >5 years (hematologic)
- IGF-1 activates PI3K/Akt/mTOR pathway promoting tumor cell proliferation and angiogenesis
- Active cancer: exclude without exception. Remission: requires oncologist clearance and IGF-1 monitoring every 8 weeks.
- Glycemic Control
- Uncontrolled diabetes (HbA1c >7.5% or fasting glucose >140 mg/dL)
- Pre-diabetes (HbA1c 5.7–6.4%) or well-controlled diabetes (HbA1c <7%)
- Growth hormone opposes insulin action, increasing hepatic glucose output and reducing peripheral glucose uptake
- Uncontrolled: exclude until glycemic targets achieved. Pre-diabetes: weekly glucose monitoring first month, discontinue if fasting glucose >126 mg/dL.
- Fluid Retention
- Severe CHF (NYHA Class III–IV), nephrotic syndrome, CKD Stage 4–5
- Mild CHF (NYHA Class I–II), controlled hypertension, CKD Stage 2–3
- Growth hormone promotes renal sodium and water retention via direct tubular effects and RAAS upregulation
- Severe: exclude due to decompensation risk. Mild: acceptable if baseline fluid status stable and diuretic adjustment available.
- Thyroid Function
- Untreated hypothyroidism (TSH >10 mIU/L)
- Adequately treated hypothyroidism on stable levothyroxine dose
- Growth hormone accelerates peripheral T4 to T3 conversion, depleting T4 without replacement in hypothyroid subjects
- Untreated: exclude until TSH normalized. Treated: monitor TSH and Free T4 every 6 weeks, increase levothyroxine if TSH rises >20% from baseline.
- Joint/Nerve Compression
- Severe carpal tunnel syndrome requiring surgical decompression
- Mild carpal tunnel or arthropathy with baseline symptoms documented
- Growth hormone-induced soft tissue and cartilage hypertrophy compresses median nerve and inflames joint spaces
- Severe: exclude or defer until after surgical correction. Mild: document baseline with validated scales, discontinue if symptoms progress beyond 2-point increase.